Because the expertise of its medical professionals is widely acknowledged, Cedars-Sinai is an important hub in the world of kidney transplantation research. Drug companies, scientists from other institutions, technology experts and equipment makers regularly come to our scientific labs to test new protocols and procedures.
Cedars-Sinai is honored to have been awarded two of the five available controlled clinical trials grants in kidney transplantation from the National Institutes of Health. Each trial, one for pediatric patients and one for adults, studies transplant immunotherapy protocols developed at Cedars-Sinai. The trial is examining the ability of intravenous gamma globulin (IVIG) to lower antibodies that cause kidney transplant rejections.
For more information about our clinical research in kidney transplantation, please contact us at 800-303-6235 or 310-423-2641.
Active Clinical Trials
- Investigator initiated/hansa medical.
A Phase I/II Trial to Evaluate the Safety and Tolerability of IdeS (IgG endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly HLA Sensitized Patients; NCT 02475551. 2015.
- Hansa medical sponsored.
A Phase II Study to Evaluate the Efficacy of IdeS (IgG endopeptidase) to Desensitize Transplant Patients with a Positive Crossmatch Test. 2016.
- Genenetech sponsored.
A Phase Ib, Single- and Multiple-Dose, Open Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Obinituzumab in Adults With ESRD and Hypersensitization Awaiting Renal Transplantation. 2015.
- NIH grant (Collaboration with University of California, San Francisco): co-principal investigators.
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts U01 AI113362-01: T-regulatory Cells (TASK) and Tocilizumab (TRAIL). 2016.